TRAW
What one share of Traws Pharma holds
Pharmaceutical Preparations
Traws Pharma, Inc. (“Traws,” “we,” or the “Company”) is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health.
Traws Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.47 |
|---|---|
| Cash and investments | $0.33 |
| Book value | $0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$1,871 | — | −$2,064 | — | $356.02 |
| 2019 | — | −$560.58 | $1.43 | −$544.49 | — | — |
| 2020 | $0.50 | −$54.21 | $0.03 | −$49.75 | — | $12.45 |
| 2021 | $0.34 | −$24.01 | — | −$28.94 | — | $55.18 |
| 2022 | $0.27 | −$22.68 | — | −$19.48 | — | $33.82 |
| 2023 | $0.27 | −$22.57 | $0.02 | −$21.38 | — | $12.70 |
| 2024 | $0.15 | −$35.21 | $2.35 | −$21.54 | — | — |
| 2025 | $0.33 | $0.82 | $0.31 | −$2.48 | — | −$0.07 |